aMMbition

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Arms / Cohorts

Experimental:Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental:Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Patient Screener(888) 850-0650

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.